This resource will help long-term care facilities work through the process of considering therapeutic treatments for residents who test positive for COVID-19 through PCR or rapid testing.
What are COVID-19 treatments?
COVID-19 treatments include monoclonal antibody therapy and antivirals. These can help prevent severe illness for some people who get infected with COVID-19 and are not yet hospitalized.
The Food and Drug administration (FDA) authorized or approved several treatments for certain patients with COVID-19. At this time, Colorado receives distributions from the federal level of the following therapeutics: bebtelovimab, Paxlovid, and molnupiravir.
These treatments are then allocated to enrolled COVID-19 therapeutics providers, long-term care pharmacies, and retail pharmacies from the state of Colorado or directly from the federal level.
The FDA also authorized Evusheld, which can be used to help prevent COVID-19 in people who are moderately to severely immunocompromised or are unable to be vaccinated due to a severe allergy. Evusheld is also allocated by CDPHE.
In addition, remdesivir, an FDA-approved antiviral COVID-19 treatment, can be ordered directly from the manufacturer.
- Paxlovid is a pill for people who test positive for COVID-19, have mild or moderate symptoms, and have at least one risk factor for progression to severe disease. People aged 12 years or older who weigh at least 40 kilograms (about 88 pounds) can take Paxlovid.
- Molnupiravir (Lagevrio) is a pill for people who test positive for COVID-19, are experiencing mild or moderate symptoms, have at least one risk factor for progression to severe disease, and cannot receive other FDA authorized COVID-19 treatments. Adults aged 18 years and older can take molnupiravir.
- Remdesivir (Veklury) is an IV infusion given once a day for three days for people who test positive for COVID-19, are experiencing mild to moderate symptoms, and have at least one risk factor for progression to severe disease. Remdesivir can be given to adults and children 28 days of age and older and weighing at least 3 kg. [Remdesivir (Veklury) must be ordered directly from the manufacturer. It is not distributed to the state from the federal level.
- Bebtelovimab is an IV infusion for people who test positive for COVID-19, are experiencing mild to moderate symptoms, have at least one risk factor for progression to severe disease, and who cannot receive other FDA authorized COVID-19 treatments.
- Evusheld is a medication to prevent certain people from getting COVID-19. It is administered as two separate intramuscular (IM) injections for people who are moderately to severely immunocompromised or for people who can’t get vaccinated against COVID-19. Evusheld can prevent COVID-19. It isn’t for people who already have COVID-19 or were recently exposed to COVID-19.
Who can receive COVID-19 treatments?
Treatment is for people who test positive for COVID-19, currently have mild to moderate symptoms, and have at least one risk factor for progression to severe disease. Most of these treatments are not for people who are currently hospitalized for COVID-19.
It is important to test early for COVID-19 and see a health care provider to determine if you would benefit from treatment. See People with Certain Medical Conditions and CombatCOVID.hhs.gov to learn more.
CDPHE’s COVID-19 treatments webpage provides information about each treatment.
What should a facility do when a resident tests positive for COVID-19?
Early testing and evaluation by a health care provider for treatment is important because these medications must be given within a few days of when symptoms begin.
If a resident tests positive for COVID-19, contact the resident’s health care provider and/or your facility medical director and ask about treatment as soon as you can. If the resident is eligible, a prescription (or order) from the resident’s health care provider will be needed.
Where can a facility get COVID-19 treatment for a resident?
Contact your long-term care pharmacy, a local pharmacy typically utilized for resident medications, and/or review the list of providers with inventory on CDPHE’s COVID-19 treatments webpage.
Contact your pharmacy now so you’ll be ready to access treatment options if a resident tests positive for COVID-19..
To prevent delayed treatment, discuss therapeutics with your residents and residents’ decision makers now. This conversation can be used to obtain consent for treatment in case a resident tests positive for COVID-19.
The following maps and this list of long-term care facility pharmacies can be used to find a COVID-19 treatment provider near you:
Gray pins = Long term care facilities
Purple crosses = Test to Treat providers
Green crosses = Monoclonal antibody treatment (Bebtelovimab)
Yellow crosses = Preventive monoclonal antibody therapy (Evusheld)
Blue crosses = Oral antivirals (Paxlovid and/or molnupiravir)
Orange crosses = Providers with multiple treatment types
Brown crosses = Long term care pharmacies
Brown zones = Long term care pharmacies area of coverage
How can my skilled nursing facility or my long-term care pharmacy enroll to become a COVID-19 treatment provider?
Providers who are interested in ordering COVID-19 therapeutics can request an account using this form. Once enrolled, there are utilization reporting requirements at the state and federal levels. For questions about the COVID-19 therapeutics program, email email@example.com.
- CDPHE COVID-19 Therapeutics Talking Points
- CDPHE Prevention and Treatment Toolkit
- CDC Health Alert Network (HAN) - Updated Information on Availability and Use of Treatments for Outpatients with Mild to Moderate COVID-19 Who are at Increased Risk for Severe Outcomes of COVID-19
- NIH Therapeutic Management of Nonhospitalized Adults with COVID-19
- FDA PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers
- ASPR COVID-19 Outpatient Therapeutics Consider one of the following therapeutics, if available, feasible, and clinically appropriate1: Clinical Decision Aid for Ages 12+
- CDC Health Alert Network (HAN) - COVID-19 Rebound After Paxlovid Treatment
- Please direct questions about COVID-19 therapeutics in residential care settings to firstname.lastname@example.org.
- The COVID-19 Medical Guidance team is available for consultations with facility medical directors and/or resident health care providers about therapeutics, contact email@example.com